Thanks to the drug’s wide range of uses, the cancer community may soon rethink the treatment of various types of cancer.
Clinical Trials Arena writes that French biotech company Nanobiotix and University of Texas Cancer Center Anderson are collaborating on Stage 1 and Stage 2 trials of a new drug to treat solid cancers that have spread to the lungs and liver.
Focus.Technologies own telegraph channel. Subscribe so you don’t miss the latest and exciting news from the world of science!
NBTXR3 consists of so-called functionalized hafnium oxide nanoparticles. This is a new oncological drug, if you do not delve into the terminology-filled scientific resources. It is given to the patient as a single injection directly into the tumor and then triggered by radiotherapy.
One of the great things about the NBTXR3 is its potential scalability. Due to its physical principle of action, it can be applied to any solid tumor suitable for radiotherapy. This wide range of applications combined with an innovative mechanism of action makes NBTXR3 a potential champion in the fight against cancer.
Moreover, Nanobiotix and Anderson Cancer Center experts will not stop at one test. They plan to conduct several other NBTXR3 clinical trials as they scale their research. For example, they plan to conduct a phase II trial of NBTXR3 in combination with anti-PD-1 for patients with recurrent or metastatic head and neck cancer. The goals of the scientists do not end there: first-stage trials for patients with pancreatic cancer are planned, as well as the use of the drug in combination with chemotherapy for esophageal cancer.
This groundbreaking research and development of NBTXR3 is already generating worldwide interest. In 2021, Nanobiotix together with LianBio brought the development of NBTXR3 to the markets of Greater China and other Asian countries. And earlier this year, Nanobiotix partnered with Janssen Pharmaceutica to jointly develop and market NBTXR3 globally.
Leonard Farber, director of clinical and medical affairs at Nanobiotix, shares the company’s hopes to bring the potential benefits of NBTXR3 to millions of patients worldwide. Given the company’s pace of development and the promising nature of its research, this could become a reality sooner than we think.
While this is an exciting step forward, we must remember that NBTXR3 trials are still in their infancy. While the potential benefits and applications of this therapy are promising, more validation and testing is needed before we can fully understand its effect and identify potential serious side effects. But these events are a reminder that advances in biotechnology continue to push the boundaries of what is possible in the treatment of cancer every day and bring hope to millions of people whose lives are held hostage by a relentless disease.
Previously Focus He wrote about the cancer tsunami among the elderly that will sweep the world by 2040. And this could test the sustainability of different countries’ health systems, experts warn.
Moreover Focus He wrote about a new way to test for cancer at home that requires only one test. Researchers believe the new technology could detect cancer at an early stage.
This material is for informational purposes only and does not contain advice that may affect your health. If you have problems, contact a professional.
Source: Focus
Ashley Fitzgerald is an accomplished journalist in the field of technology. She currently works as a writer at 24 news breaker. With a deep understanding of the latest technology developments, Ashley’s writing provides readers with insightful analysis and unique perspectives on the industry.